Aurora Cannabis Inc.

NYSE: ACB
$11.77
-$0.39 (-3.2%)
Closing price July 9, 2020
Wednesday's top analyst upgrades and downgrades included Amazon.com, Aurora Cannabis, Comcast, Dick's Sporting Goods, Morgan Stanley, Nike, Nio, Plug Power, Snap and Walt Disney.
What does it say about long-term industry expectations when a leader in the cannabis field is laying off more employees and closing plants as a restructuring effort?
Aphria, an analyst favorite among pot stocks, rallies after market selloff Thursday.
Cannabis stocks in general stumbled in the latter half of last year. Wall Street expects profits, and none of these companies is anywhere near profitability. In the United States, high state and...
There may be a new dawn for Aurora Cannabis as online sales rise, new retail outlets open, and Reliva deal offers access to U.S. market.
Aurora Cannabis closed its acquisition of Reliva ahead of schedule but poor results from Canopy Growth may have dinged pot stocks.
The May 15 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks decreased, and in one stock incredibly.
The euphoria that followed the announcement Wednesday that Aurora Cannabis is acquiring Reliva was subsiding Friday.
Friday's top analyst upgrades and downgrades included Agilent Technologies, Aurora Cannabis, Best Buy, Box, Marvell Technology, Nvidia, Palo Alto Networks, Roku, Splunk and TJX Companies.
Aphria stays strong while Green Growth, which tried to buy it, goes bust. Canadian rival Aurora buys U.S. hemp retailer Reliva.
Investors can’t figure out if it’s dawn or dusk for Aurora Cannabis, and that means a wild ride for the stock.
High times in hard times? Tilray says pot should be seen as a consumer staple rather than an indulgence.
Canadian pot company Aphria is well positioned in the medical and recreational sectors. It has eyes on Europe but the coronavirus has stalled legalization efforts in the U.S.
Canadian pot grower Aurora Cannabis posted a solid beat over analysts' revenue expectations and shares are booming as a result.
Cannabis stocks have disappointed but the coronavirus lockdown might boost consumer demand.